In development: Guidance, quality standards and advice
Showing 1 to 3 of 3
| Title | Type | Expected publication date |
|---|---|---|
| Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance | |
| Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586] | Technology appraisal guidance | |
| Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413 | Technology appraisal guidance |